2025
Glucagon-like peptide-1 receptor agonists but not dipeptidyl peptidase-4 inhibitors reduce alcohol intake
Farokhnia M, Tazare J, Pince C, Bruns N, Gray J, Re V, Fiellin D, Kranzler H, Koob G, Justice A, Vendruscolo L, Rentsch C, Leggio L. Glucagon-like peptide-1 receptor agonists but not dipeptidyl peptidase-4 inhibitors reduce alcohol intake. Journal Of Clinical Investigation 2025 PMID: 40048376, DOI: 10.1172/jci188314.Peer-Reviewed Original ResearchAlcohol use disorderTreat alcohol use disorderGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsPeptidase-4 inhibitorsDPP-4isOperant oral alcohol self-administrationDPP-4iAlcohol intakeOral alcohol self-administrationBinge-like alcohol drinkingBaseline alcohol use disordersReceptor agonistsAlcohol self-administrationAlcohol-dependent ratsReduce alcohol drinkingAlcohol drinkingGLP-1RAAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) scoresReduce alcohol intakeGLP-1RAsImpact of dipeptidyl peptidase-4 inhibitorReverse translational approachBaseline hazardous drinkingED Use of Extended-Release 7-Day Injectable Buprenorphine for Minimal Opioid Withdrawal
D'Onofrio, Herring A, Perrone J, Hawk K, Samuels E, Cowan E, Anderson E, McCormack R, Huntley K, Owens P, Martel S, Schactman M, Lofwall M, Walsh S, Dziura J, Fiellin D. ED Use of Extended-Release 7-Day Injectable Buprenorphine for Minimal Opioid Withdrawal. Drug And Alcohol Dependence 2025, 267: 112200. DOI: 10.1016/j.drugalcdep.2024.112200.Peer-Reviewed Original ResearchM12 Contingency Management With Stepped Care for Unhealthy Alcohol Use Among Individuals With HIV: Initial Findings From a Multisite Randomized Controlled Trial
Edelman E, Dziura J, Deng Y, DePhilippis D, Brown S, Ferguson T, Marconi V, Goetz M, Rodriguez-Barradas M, Simberkoff M, Molina P, Weintrob A, Maisto S, Paris M, Justice A, Bryant K, Fiellin D. M12 Contingency Management With Stepped Care for Unhealthy Alcohol Use Among Individuals With HIV: Initial Findings From a Multisite Randomized Controlled Trial. Drug And Alcohol Dependence 2025, 267: 111606. DOI: 10.1016/j.drugalcdep.2024.111606.Peer-Reviewed Original ResearchT107 Beyond Rest: Unraveling the Nexus of Sleep Deficiency, Environment, Control, and their Influence on Opioid Use Disorder Treatment Outcomes
Elumn J, Cohen I, JadKarim L, Puglisi L, Lin H, Fiellin D, Yaggi K, Wang E. T107 Beyond Rest: Unraveling the Nexus of Sleep Deficiency, Environment, Control, and their Influence on Opioid Use Disorder Treatment Outcomes. Drug And Alcohol Dependence 2025, 267: 111875. DOI: 10.1016/j.drugalcdep.2024.111875.Peer-Reviewed Original ResearchIntegrated Stepped Alcohol Treatment With Contingency Management for Unhealthy Alcohol Use Among People With HIV: A Randomized Controlled Trial
Edelman E, Dziura J, Deng Y, DePhilippis D, Ferguson T, Brown S, Marconi V, Goetz M, Rodriguez-Barradas M, Simberkoff M, Molina P, Weintrob A, Maisto S, Paris M, Justice A, Bryant K, Fiellin D. Integrated Stepped Alcohol Treatment With Contingency Management for Unhealthy Alcohol Use Among People With HIV: A Randomized Controlled Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2025, 98: 72-81. PMID: 39321757, DOI: 10.1097/qai.0000000000003534.Peer-Reviewed Original ResearchUnhealthy alcohol useSelf-reported abstinenceAlcohol useLost to follow-upContingency managementAlcohol use disorderRandomized controlled trialsSubstance use treatmentAlcohol abstinenceFollow-upUse disorderControlled trialsPWHAlcohol treatmentAbstinenceUse treatmentEvidence of abstinenceHIVWeeksMean proportionTreatmentTrialsAlcoholDaysParticipants
2024
Four targets: an enhanced framework for guiding causal inference from observational data
Lu H, Li F, Lesko C, Fink D, Rudolph K, Harhay M, Rentsch C, Fiellin D, Gonsalves G. Four targets: an enhanced framework for guiding causal inference from observational data. International Journal Of Epidemiology 2024, 54: dyaf003. PMID: 39868475, PMCID: PMC11769716, DOI: 10.1093/ije/dyaf003.Peer-Reviewed Original ResearchGuideline concordance of electronic health record order sets for hospital‐based treatment of alcohol withdrawal syndrome
Cohen S, Kashyap N, Steel T, Edelman E, Fiellin D, Joudrey P. Guideline concordance of electronic health record order sets for hospital‐based treatment of alcohol withdrawal syndrome. Journal Of Hospital Medicine 2024 PMID: 39580659, DOI: 10.1002/jhm.13556.Peer-Reviewed Original ResearchElectronic health recordsElectronic health record ordersTreatment of alcohol withdrawal syndromeSevere alcohol withdrawal syndromeTreatment of unhealthy alcohol useAlcohol withdrawal syndromeUnhealthy alcohol useAcute care hospitalsHospital organizationCross-sectional studyHospital-based treatmentCare practicesHealth recordsCare escalationGuideline concordanceSymptom assessmentCare hospitalProtocolized careRecord ordersAlcohol use disorderSymptom scoresAlcohol useSubstance useHospitalInconsistent definitionsCost-Effectiveness of Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder
Lu T, Ryan D, Cadet T, Chawarski M, Coupet E, Edelman E, Hawk K, Huntley K, Jalali A, O'Connor P, Owens P, Martel S, Fiellin D, D'Onofrio G, Murphy S. Cost-Effectiveness of Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder. Annals Of Emergency Medicine 2024, 85: 205-213. PMID: 39570250, PMCID: PMC11845297, DOI: 10.1016/j.annemergmed.2024.10.001.Peer-Reviewed Original ResearchHealth care sector perspectiveImplementation facilitatorsOpioid use disorder careIncremental cost-effectiveness ratioCost-effectiveness ratioHealth care sector costsEducational strategiesImplementation facilitation strategyCost-effectiveness acceptability curvesLikelihood of cost-effectivenessCost-effectiveOpioid use disorderQuality-adjusted life yearsUse disorderPatient engagementAcademic EDED visitsAcceptability curvesStandard educationEmergency departmentLife yearsFacilitation strategiesMeasures of effectivenessHealthBuprenorphineAvailability of Medications for Opioid Use Disorder in US Psychiatric Hospitals
Cohen S, Beetham T, Fiellin D, Muvvala S. Availability of Medications for Opioid Use Disorder in US Psychiatric Hospitals. JAMA Network Open 2024, 7: e2444679. PMID: 39535800, PMCID: PMC11561693, DOI: 10.1001/jamanetworkopen.2024.44679.Peer-Reviewed Original ResearchClinician and Practice Characteristics Associated With Support of Office-based Methadone: Findings From a National Survey
Sung M, Black A, Blevins D, Henry B, Cates-Wessel K, Dawes M, Hagle H, Joudrey P, Molfenter T, Levin F, Fiellin D, Edelman E. Clinician and Practice Characteristics Associated With Support of Office-based Methadone: Findings From a National Survey. Journal Of Addiction Medicine 2024, 19: 150-156. PMID: 39475119, PMCID: PMC11903189, DOI: 10.1097/adm.0000000000001388.Peer-Reviewed Original ResearchOpioid use disorderCharacteristics associated with supportTreatment of opioid use disorderMultivariate logistic regression modelOffice-based settingSequential multivariable logistic regression modelsOpioid treatment programsLogistic regression modelsAcademic medical centerUse disorderInclusion criteriaMethadoneMedical CenterPatientsOffice-basedCOVID-19 surveyClinician supportPractice characteristicsLongitudinal treatmentImplementation barriersPolicy changesMOUDOutcome variablesImprove accessNational surveyThe Feasibility and Acceptability of a Clinical Pharmacist-delivered Intervention to Reduce Bothersome Health Symptoms from Polypharmacy and Alcohol Use and Communicate Risk among People with HIV: Pilot Study Protocol
Womack J, Leblanc M, Sager A, Zaets L, Maisto S, Garcia A, Aoun-Barakat L, Brown S, Edelman E, Fiellin D, Fisher J, Fraenkel L, Kidwai-Khan F, Marconi V, Martino S, Pulk R, Satre D, Virata M, Justice A, Hsieh E. The Feasibility and Acceptability of a Clinical Pharmacist-delivered Intervention to Reduce Bothersome Health Symptoms from Polypharmacy and Alcohol Use and Communicate Risk among People with HIV: Pilot Study Protocol. AIDS And Behavior 2024, 29: 482-496. PMID: 39465468, DOI: 10.1007/s10461-024-04533-6.Peer-Reviewed Original ResearchUnhealthy alcohol useAlcohol usePharmacist-delivered interventionVeterans Aging Cohort StudyPilot study protocolStudy protocolElectronic health recordsSupport behavior changePre-test/post-test designAging Cohort StudySelf-administered surveyAlcohol use disorderAlcohol Research CenterBothersome symptomsPre-test/post-testCommunicating riskHealth recordsLong-term medicationHealth symptomsCounseling interventionCounseling sessionsSessions 2 weeksQualitative interviewsAlcohol consumptionUse disorderTreatment Failure Versus Failed Treatments: The Risks of Embracing Treatment Refractory Addiction
Fiellin D. Treatment Failure Versus Failed Treatments: The Risks of Embracing Treatment Refractory Addiction. Journal Of Addiction Medicine 2024, 18: 480-482. PMID: 39356618, DOI: 10.1097/adm.0000000000001351.Peer-Reviewed Original ResearchW81 Implementation Facilitation Improves Clinician Readiness to Provide Emergency Department-Initiated Buprenorphine in Four Urban Academic Centers
Hawk K, D'Onofrio G, Chawarski M, Coupet E, Cowan E, Curry L, Freiermurth C, Lyons M, Murphy A, O'Connor P, Richardson L, Rothman R, Whiteside L, Williams J, Fiellin D, Edelman E. W81 Implementation Facilitation Improves Clinician Readiness to Provide Emergency Department-Initiated Buprenorphine in Four Urban Academic Centers. Drug And Alcohol Dependence 2024, 260: 110699. DOI: 10.1016/j.drugalcdep.2023.110699.Peer-Reviewed Original ResearchT50 Receipt of Prescribed Opioids and Benzodiazepines After Non-Fatal Overdose and Risk of Subsequent Overdose
Howell B, Black A, Lin H, Lauretta G, Heimer R, Hawk K, D'Onofrio G, Fiellin D, Becker W. T50 Receipt of Prescribed Opioids and Benzodiazepines After Non-Fatal Overdose and Risk of Subsequent Overdose. Drug And Alcohol Dependence 2024, 260: 110499. DOI: 10.1016/j.drugalcdep.2023.110499.Peer-Reviewed Original ResearchW31 The Impact of Tobacco Use on Liver-Related Morbidity in Patients With Cirrhosis
Haque L, Fiellin D, Bryant K, Edelman E, Justice A, Lim J, Re V, Marshall B, Taddei T, Tate J, Tetrault J, Williams E, McGinnis K. W31 The Impact of Tobacco Use on Liver-Related Morbidity in Patients With Cirrhosis. Drug And Alcohol Dependence 2024, 260: 110649. DOI: 10.1016/j.drugalcdep.2023.110649.Peer-Reviewed Original ResearchS96 The Pharmacist-Integrated Medication Treatment for Opioid Use Disorder (PrIMO) Model: Operationalizing an Effective Clinical Care Model to Assess Feasibility in Diverse Care Settings
Homsted F, Gardner T, Nesin N, McGrady F, Fiellin D, Joudrey P, McLeman B, Gauthier P, Moore S, Marsch L, Ghitza U, Rao D. S96 The Pharmacist-Integrated Medication Treatment for Opioid Use Disorder (PrIMO) Model: Operationalizing an Effective Clinical Care Model to Assess Feasibility in Diverse Care Settings. Drug And Alcohol Dependence 2024, 260: 110207. DOI: 10.1016/j.drugalcdep.2023.110207.Peer-Reviewed Original ResearchW80 Buprenorphine-Naloxone vs. Extended-Release Naltrexone for Opioid Use Disorder in People With Recent Criminal Legal Involvement: A Secondary Analysis of the X:BOT Randomized Controlled Trial
Balter D, Puglisi L, Dziura J, Fiellin D, Howell B. W80 Buprenorphine-Naloxone vs. Extended-Release Naltrexone for Opioid Use Disorder in People With Recent Criminal Legal Involvement: A Secondary Analysis of the X:BOT Randomized Controlled Trial. Drug And Alcohol Dependence 2024, 260: 110698. DOI: 10.1016/j.drugalcdep.2023.110698.Peer-Reviewed Original ResearchExtended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal
D’Onofrio G, Herring A, Perrone J, Hawk K, Samuels E, Cowan E, Anderson E, McCormack R, Huntley K, Owens P, Martel S, Schactman M, Lofwall M, Walsh S, Dziura J, Fiellin D. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. JAMA Network Open 2024, 7: e2420702. PMID: 38976265, PMCID: PMC11231806, DOI: 10.1001/jamanetworkopen.2024.20702.Peer-Reviewed Original ResearchConceptsClinical Opiate Withdrawal ScaleExtended-release buprenorphineOpioid use disorderPrecipitated withdrawalOpioid withdrawalOpioid use disorder treatmentCow scoreClinical Opiate Withdrawal Scale scoreAdverse eventsNonrandomized trialsSevere opioid use disorderDays of opioid useOpiate Withdrawal ScaleModerate to severe opioid use disorderFormulation of buprenorphineOpioid use disorder careWithdrawal ScaleUse disorderAssociated with medicationsNonprescribed opioidsPain scoresExtended-releaseInjection painOpioid useAdult patientsBuprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial
Balter D, Puglisi L, Dziura J, Fiellin D, Howell B. Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial. Journal Of Substance Use And Addiction Treatment 2024, 164: 209438. PMID: 38857827, PMCID: PMC11300157, DOI: 10.1016/j.josat.2024.209438.Peer-Reviewed Original ResearchXR-NTXBuprenorphine-naloxoneOpioid use disorderCriminal legal involvementUse disorderHazard of overdoseLifetime incarcerationLegal involvementOpioid use disorder treatment outcomesPer-protocol analysisExtended-release naltrexoneMOUD effectivenessTreatment outcomesEffects of medicationHazard of relapseSecondary analysisIntention-to-treat analysisIntention-to-treatRandomized controlled trialsEffects of MOUDRelapseControlled trialsDisordersOpioidPotential effect modifiersPrescription Opioid Dose Change Before Fatal Opioid-Detected Overdose.
Kazemitabar M, Howell B, Becker W, Lin H, Grau L, Heimer R, D'Onofrio G, Hawk K, Fiellin D, Black A. Prescription Opioid Dose Change Before Fatal Opioid-Detected Overdose. Journal Of Studies On Alcohol And Drugs 2024, 85: 815-819. PMID: 38775307, DOI: 10.15288/jsad.24-00026.Peer-Reviewed Original ResearchPrescribed opioidsOpioid dose changesRapid dose increaseNon-HispanicOverdose deathsToxicological resultsNon-prescription opioidsBlack non-HispanicMorphine equivalentsOpioid therapyWhite non-HispanicDose changesDaily doseMean ageDispensed opioidsPrescription opioidsPrescribing patternsOpioidDose increaseOpioid overdose crisisIncreasing dosesStudy investigated patternsEffect of timeEffects of ageSecondary analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply